Author

Y. Moskovitz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:differential expression· 1 Assay:imaging· 1

Frequent Co-Authors

L. I. Shlush· 2 shared N. Kaushansky· 2 shared A. Plotnikov· 1 shared A. Tuval· 1 shared B. Geiger· 1 shared B. Haim· 1 shared D. Leshkowitz· 1 shared E. P. Papapetrou· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

L. I. Shlush

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Rock inhibitors target SRSF2 leukemia by disrupting cell mitosis and nuclear morphology

M. Su, T. Fleisher, I. Grosheva, M. B. Horev, M. Olszewska, B. Haim, A. Plotnikov, S. Carvalho, Y. Moskovitz, M. Minden, N. Chapal-Ilani, E. P. Papapetrou, N. Dezorella, T. Cheng, N. Kaushansky, , L. I. Shlush

This study identifies ROCK inhibitors as effective targeting agents for SRSF2 mutant leukemia by disrupting mitosis and nuclear morphology in vitro and in xenograft models.

bioRxiv · Feb 15, 2022 · PreprintCancer Biology

Pseudo-mutant p53 as a targetable phenotype of DNMT3A-mutated pre-leukemia

A. Tuval, Y. Brilon, H. Ezogy, Y. Moskovitz, T. Biezuner, D. Leshkowitz, T. M. Salame, M. D. Minden, P. Tal, V. Rotter, M. Oren, N. Kaushansky, L. I. Shlush

The paper identifies a pseudomutant p53 conformation in DNMT3A-mutated pre-leukemic HSPCs and shows that shifting to the wild-type conformation can eliminate these cells.

bioRxiv · May 30, 2021 · PreprintCancer Biology